The Immunoreactivity of Uroplakin III in Urothelial Carcinoma of Urinary Bladder and Other Non- Urothelial Carcinoma

Abstract

The aim of present study is evaluate the sensitivity and specificity of uroplakin III marker in the urothelial
cancer patients, and to show whether there is association this marker with their clinicopathological parameters.
This study is a retrospective (70 cases) of whom diagnosis as urothelial carcinoma of urinary bladder (male
41 and female 29 ) with added normal urothelial tissue and breast tissue were taken as control group. 41
nonurothelial carcinoma are also involved. All paraffin blocks which diagnosed as urothelial carcinoma
were supported the diagnosis by pathologist. The all research materials are applied according to protocol
from, Bio SB, Inc. Uroplakin III immunoreactivity assessment is depend on staining intensity and the
positive percentage tumor cells. The age group between 64-75 years old reveals highest positive value 18
(42.9%). Uroplakin III expressions sensitivity is 44.3% , and it has higher positive percentage in low grade
20 (47.6%) in comparison with high grade 11(39.3%) but without significant difference (p = 0.492). Ta-1
and T2 Tumor stage show 26 (46.4%) and 5(35.7%) positive uroplakin III staining respectively, with no
statistical association between them (p = 0.47). The all non-urothelial carcinoma show negative result
(100% specificity). expression of uroplakin III with mild sensitivity and high specificity, it is regarded as
good marker (even with mild sensitivity) for differentiation between primary urothelial carcinoma from
other urological cancers in same site, and it can be useful for diagnosis of unkown metastatic cancer because
of high specificity of uroplakin III.